Citigroup Maintains Neutral on Hologic, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has maintained a Neutral rating on Hologic (NASDAQ:HOLX) and lowered the price target from $90 to $85.

August 04, 2023 | 9:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup has maintained a Neutral rating on Hologic and lowered the price target from $90 to $85.
The news directly pertains to Hologic as Citigroup has maintained a Neutral rating on the company and lowered the price target. This could potentially impact investor sentiment and the stock's price in the short term, although the Neutral rating suggests that the overall outlook for the company remains unchanged.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100